Loading
A phase 1/2 trial of B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell in multiple myeloma, run by Shanghai AbelZeta Ltd., now recruiting.
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT05521802 by Shanghai AbelZeta Ltd., with 92 participants planned, started 2022-11-11 and due to reach its primary completion in 2024-07. Interventions recorded: B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell.
Shares Shanghai AbelZeta and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.